A Lifecycle Approach to Peptide Formulation in Prefilled Syringes for High-Speed Autoinjector Assembly

Peptide or protein drug substances are produced under cGMP in sterile areas meeting 21 CFR Parts 210¹ and 211² and ISO 14644³ Class 5 standards. Active ingredients and excipients are mixed using validated procedures for uniformity and stability, and then sterile filtered through 0.2 μm filter per USP <797>.⁴

Sterile solutions are filled into prefilled glass syringes in ISO Class 5 environments, often within isolators or RABS, following EU GMP Annex 1 and FDA guidance. Syringes are prepared per ISO 11040 with validated washing, siliconization, and depyrogenation, meeting USP <85>⁵ and <1228>⁶/<1229>.⁷ Accurate doses are dispensed with validated systems (ICH Q2,⁸ FDA Process Validation Guidance⁹), then stoppered with closures compliant with ISO 8362¹⁰ and USP <381>¹¹/<382>,¹² and container closure integrity verified per USP <1207>.¹³

In-process controls include fill volume, stopper position, and particulate inspection per USP <788>¹⁴/<790>.¹⁵ Environmental monitoring is conducted per EU GMP Annex 1,¹⁶ ISO 14644,³ and ISO 14698,¹⁷ with media fills for sterility assurance. Filled syringes undergo QC for sterility, endotoxins (USP <71>,¹⁸ <85>⁵), dose accuracy, and visual quality before integration into autoinjectors built under ISO 13485¹⁹ and ISO 11608,²⁰ with biocompatibility per ISO 10993.²¹

Autoinjectors are assembled in ISO 14644³ Class 7 environments using validated equipment, and each unit is tested for injection force, delivery time, and safety per ISO 11608²⁰ and FDA guidance. Stability studies follow ICH Q1A.²² Release occurs only after all sterility, functional, and quality checks pass.

Formulations maintain stability, dose accuracy, and device compatibility under ICH Q6B,²³ ICH Q8,²⁴ ICH Q9,²⁵ ICH Q10,²⁶ and ICH Q1A²²/ICH Q5C.²⁷ Buffers, pH, stabilizers, and surfactants control degradation and adsorption. High peptide concentration increases viscosity, affecting filling, syringe performance, and needle injection, evaluated per ISO 11608.²⁰ Particulates are controlled per USP<788>,¹⁴ USP<790>,¹⁵ USP<787>,²⁸ and container compatibility verified via adsorption, extractables/leachables (USP<1663>,²⁹ USP<1664>³⁰), CCI (USP<1207>¹³), and elastomer compliance (USP<381>¹¹/USP<382>¹²), ensuring stability and safety throughout shelf life.

Having outlined formulation requirements, regulatory standards, and quality controls, the following sections discuss how these factors influence autoinjector performance, high-speed assembly, and factory acceptance testing. Table 1 summarizes relevant standards and guidance across the lifecycle of a peptide formulation in a prefilled syringe (PFS) and its integration into the autoinjector system.

Factors Influencing Autoinjector Performance

Peptide formulations in PFS directly impact autoinjector performance. For PFS-based autoinjectors (Figure 1), viscosity, driven by peptide concentration, affects injection force, filling accuracy, and dose delivery. Buffers and pH must be compatible with syringe materials to prevent degradation, while surfactants like polysorbates minimize adsorption and particle formation (USP<788>14, USP<790>15, USP<787>28). Plunger lubrication ensures smooth motion, and formulations must withstand shipping and handling stresses.

Injection efficiency depends on the interaction of formulation, syringe mechanics, and device design. Fine needles improve comfort but increase resistance (Hagen–Poiseuille law; Shire, et al. 2004, 1390–1402).³¹ Autoinjectors use springs to push the plunger, overcoming viscosity and plunger friction (ISO 11040³²). Shear stress, air bubbles, and temperature also influence performance. Design verification follows ISO 13485,¹⁹ with risk management per ISO 14971.³³

Engineers balance spring force, needle size, plunger friction, and viscosity to ensure reliable full-dose delivery. Typical volumes range from 0.3–1.0 mL, with springs generating 20–80 N and injection times of 5–10 seconds. Early modeling integrates these factors to ensure safe, consistent, and comfortable administration. Understanding how formulation and device design affect injection performance informs the assembly process, where precise alignment and integration of components are critical to ensuring consistent function and patient safety.

High-Speed Autoinjector Assembly

Autoinjector assembly begins with automated machines feeding and aligning components such as housings, springs, plungers, and caps. Sensors and vision systems inspect parts for correct orientation and defects, ensuring only compliant components proceed, in line with ISO 13485,¹⁹ ISO 14971,³³ and 21 CFR Part 820.³⁴ Prefilled syringes are loaded using robotic or vacuum systems designed to prevent damage and maintain sterility. Vision inspection confirms syringe quality and alignment per ISO 11040,³² while environmental controls follow 21 CFR Part 211.²

Springs are inserted and compressed using automated stations, with sensors verifying proper force and placement according to safety and GAMP 5³⁵ validation requirements. Internal components, including the syringe holder, plunger, and trigger, are assembled into the housing using precision fixtures and secured via snap-fit or welding. Alignment and design specifications are confirmed with sensors and measurements.

Completed autoinjectors are labeled and packaged, with vision systems checking accuracy and appearance. Serialization tracks each unit for full traceability, ensuring compliance with 21 CFR Part 820,³⁴ 21 CFR Part 11,³⁶ and ISO 13485.¹⁹ This process supports consistent quality, reliable device function, and regulatory compliance, forming the basis for factory acceptance testing of high-speed autoinjector equipment.

Factory Acceptance Testing (FAT)

A 100,000-unit FAT may be conducted to verify autoinjector assembly, especially for high-value, complex lines. Large FAT runs are often required when the purchase agreement or User Required Specification (URS) mandates a throughput demonstration, when the system is first-of-a-kind or high-risk, or when post-installation troubleshooting would be costly or disruptive, such as installing directly in a cGMP environment or overseas. Very expensive equipment (often $5M+) also justifies extended FAT to confirm reliability, throughput, and reject rates. Standard projects typically use smaller FAT batches of 5,000–20,000 units, with a 100,000 run reserved for commissioning or performance qualification at the manufacturing site. High-speed systems record force curves, cycle data, and alarms in the HMI, enabling engineers to detect assembly or transport deviations.³⁷ The following sections describe two critical autoinjector assembly stations and their sampling requirements.

Syringe Insertion Handling Station

This station is responsible for precisely inserting the PFS into the auto-injector housing.³⁸ The syringe typically contains the drug product and includes key components such as the glass syringe barrel, plunger stopper, needle, and needle shield. A servo-controlled robot or linear axis performs the pick-and-place operation to transfer the syringe from a tray or feeder. The system usually uses a vacuum gripper or custom end-effector designed to handle the fragile glass syringe safely. The servomotor ensures accurate positioning, smooth motion, and correct alignment during insertion into the injector body or cartridge holder. Sensors verify syringe presence, orientation, and proper seating inside the housing before the assembly proceeds to the next station. The servo operates primarily in position control mode, emphasizing precision and repeatability. If the syringe is misaligned, not fully seated, or cracked, the injector may not function correctly. Problems at this stage can lead to needle deployment issues, incomplete dose delivery, or device activation failures during later functional or destructive testing (DT). Therefore, this station ensures that the drug container (syringe assembly) is correctly positioned within the auto-injector mechanism for reliable operation.

Press-Fit Joining Station

The press-fit station assembles critical autoinjector components, such as the outer housing, spring module, actuator parts, trigger mechanism, and syringe carrier, using a servo press system.³⁷ The servo press applies precise force over a controlled distance to join each component correctly. For every part pressed, the machine records a force–displacement curve showing how the applied force changes as the component move into position. Each component has its own expected profile due to differing mechanical properties.

If the press force is too low, components like the spring module or trigger may not lock properly. If too high, parts such as the housing, syringe holder, or internal mechanisms can deform or be damaged. The system compares each curve against validated limits, flagging or rejecting devices that fall outside tolerance. Curves are stored in the HMI or quality database for traceability and process validation. Monitoring these curves helps engineers detect misaligned parts, incorrect tolerances, or damaged components, which could later cause trigger failure, incomplete needle extension, or improper drug delivery during destructive testing. By ensuring correct assembly and secure integration of mechanical and activation components, this station supports reliable autoinjector function and consistent drug delivery. To ensure the assembly processes at critical stations perform consistently across the production run, representative sampling strategies are applied.

Statistical Sampling for Critical Stations

For a FAT of 100,000 autoinjector units, stratified sampling ensures representative testing across the production run.^20,39 The run is typically divided into five strata of ~20,000 units each, capturing variations at the start, middle, and end. Non-destructive testing (NDT) is performed on 1–2% of units per stratum, verifying assembly integrity, syringe placement, press-fit quality, and vision inspection without destroying the product. Force-displacement curves for pressed components are included to monitor mechanical consistency, and NDT samples are evenly distributed to detect drift or anomalies. DT is performed on 0.1–0.5% of units per stratum, focusing on critical functions such as trigger activation, spring release, needle deployment, and dose accuracy. DT samples are evenly distributed across all strata to ensure consistent functional performance. Together, NDT and DT provide statistically significant evidence that the line produces conforming devices.

Stratified sampling follows USFDA,⁹ EMA,⁴⁰ ISO 13485,¹⁹ and GAMP 5³⁵ guidelines, balancing regulatory confidence with efficiency while avoiding full-batch destructive testing. Each stratum acts as a control segment to detect process drift or setup issues, and sample sizes align with ANSI/ASQ Z1.4⁴¹/ISO 2859-1⁴² and ISO 11608²⁰ functional testing requirements. For autoinjector assembly, five well-distributed strata are sufficient because the process is highly controlled, critical quality attributes are limited, and continuous monitoring reduces the risk of undetected variation. Adding more strata increases inspection effort with minimal additional benefit.

Statistical Analyses of Samples

Process capability (C_pK) analysis measures how well a process produces parts within specification by combining variability and centering of key parameters.⁴³ In a 100,000-unit autoinjector run, NDT samples 1–2% of units per stratum and DT samples 0.1–0.5%, across five 20,000-unit strata are typically sufficient. Continuous monitoring via force-displacement curves, sensors, and vision systems supports both C_pK calculations and functional assurance. Each stratum captures temporal process variation.

Autoinjector molds may have up to 16 cavities, so sampling represents all cavities to detect cavity-specific variation. NDT samples are distributed evenly across cavities, and DT includes units from each cavity to identify functional failures.⁴⁴ Process stability is checked using control charts, ensuring no special causes of variation. C_pK is calculated from the mean and standard deviation of mechanical parameters, either per stratum or pooled across strata and cavities. Comparing C_pK across strata and cavities detects drift, outliers, or localized issues. This stratified, cavity-aware approach ensures C_pK reflects both temporal and mold-related variation. Combined with DT results, C_pK provides robust evidence that the autoinjector production run consistently meets quality and functional specifications.

Conclusion

A coordinated approach integrating peptide formulation, PFS design, high-speed autoinjector assembly, and lifecycle-aligned regulatory compliance ensure consistent product quality, dosing accuracy, and patient safety. Applying FAT, C_pk analyses, and adherence to industry standards provides a robust framework for reliable commercial manufacturing and effective delivery of peptide therapies via autoinjectors.

References

1. 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; 2026, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210

2. 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals, 2026, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211

3. ISO 14644-1, Cleanrooms and associated controlled environments - Part 1: Classification of air cleanliness by particle concentration, 2015, https://www.iso.org/standard/53394.html

4. USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations, 2023, https://www.usp.org/compounding/general-chapter-797

5. USP General Chapter<85> Bacterial Endotoxins Test, 2024, https://www.usp.org/harmonization-standards/pdg/general-methods/bacterial-endotoxins

6. USP General Chapter<1228> Depyrogenation, 2017, https://doi.usp.org/USPNF/USPNF_M8097_03_01.html

7. USP General Chapter<1229> Sterilization of Compendial Articles, 2022, https://doi.usp.org/USPNF/USPNF_M7408_01_01.html

8.ICH Q2 Validation of Analytical Procedures, 2024, https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline

9. Process Validation: General Principles and Practices, 2011,

https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf

10. ISO 8362-2, Injection containers and accessories - Part 2: Closures for injection vials, 2024, https://www.iso.org/obp/ui/es/#iso:std:iso:8362:-2:ed-4:v1:en

11. USP General Chapter<381> Elastomeric Components in Injectable Pharmaceutical Product Packaging/Delivery Systems, 2024, https://doi.usp.org/USPNF/USPNF_M99140_60201_01.html

12. USP General Chapter<382> Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems, 2025, https://doi.usp.org/USPNF/USPNF_M11355_04_01.html

13. USP General Chapter<1207> Package Integrity Evaluation—Sterile Products, 2017, https://doi.usp.org/USPNF/USPNF_M99926_01_01.html

14. USP General Chapter<788> Subvisible Particulate Matter in Injections, 2026,

https://www.usp.org/harmonization-standards/pdg/general-methods/particulate-contamination

15. USP General Chapter<790> Visible Particulates in Injections, 2017, https://doi.usp.org/USPNF/USPNF_M7197_01_01.html

16. EU GMP Annex 1, Manufacture of Sterile Medicinal Products, 2022, https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf

17. ISO 14698-1, Cleanrooms and associated controlled environments, 2003, https://www.iso.org/obp/ui/#iso:std:iso:14698:-1:ed-1:v1:en

18. USP General Chapter<71> Sterility Tests, 2016,

https://www.usp.org/harmonization-standards/pdg/general-methods/sterility-test

19. ISO 13485, Medical Devices - Quality Management Systems, 2016, https://www.iso.org/standard/59752.html

20. ISO 11608, Needle-based Injection Systems for Medical Use - Requirements and Test Methods 2022, https://www.iso.org/standard/70733.html

21. ISO 10993, Biological evaluation of medical devices, 2025, https://www.iso.org/standard/10993-1

22. ICH Q1A Stability Testing of New Drug Substances and Drug Products, 2003,

https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline

23. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, 1999, https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products-scientific-guideline

24. ICH Q8 Pharmaceutical Development, 2006, https://www.ema.europa.eu/en/ich-q8-r2-pharmaceutical-development-scientific-guideline

25. ICH Q9 Quality Risk Management, 2023, https://www.ema.europa.eu/en/ich-q9-quality-risk-management-scientific-guideline

26. ICH Q10 Pharmaceutical Quality System, 2008, https://www.ema.europa.eu/en/ich-q10-pharmaceutical-quality-system-scientific-guideline

27. ICH Q5C Stability Testing of Biotechnological/Biological Products, 1996, https://www.ema.europa.eu/en/ich-q5c-stability-testing-biotechnological-biological-products-scientific-guideline

28. USP General Chapter <787> Subvisible Particulate Matter in Therapeutic Protein Injections, 2020, https://doi.usp.org/USPNF/USPNF_M6497_02_01.html

29. USP General Chapter<1663> Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems, 2020, https://doi.usp.org/USPNF/USPNF_M7126_03_01.html

30. USP General Chapter<1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems, 2024, https://doi.usp.org/USPNF/USPNF_M7127_03_01.html

31. Shire, S.J; Shahrokh, Z.; and Liu, J. Challenges in the development of high protein concentration formulations,Journal of Pharmaceutical Sciences, 2004, 93 (6), pp. 1390–1402, https://pubmed.ncbi.nlm.nih.gov/15124199/

32. ISO 11040-8, Prefilled Syringes: Requirements and Test Methods for Finished Prefilled Syringes, 2026, https://www.iso.org/standard/85862.html

33. ISO 14971 Medical devices - Application of Risk Management to Medical Devices, 2019, https://www.iso.org/standard/72704.html

34. 21 CFR Part 820, Quality Management System Regulation, 2026, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820

35. ISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems, 2^nd Edition, 2022, https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571

36. 21 CFR Part 11, Electronic Records; Electronic Signatures, 2026, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11

37. J. Sprovieri, Servo Presses Aid Assembly of Autoinjectors, 2022, Assembly Magazine, https://www.assemblymag.com/articles/97398-servo-presses-aid-assembly-of-autoinjectors

38. Gerresheimer’s, Adapter Aids Positioning of Syringes in Autoinjectors, Pharmaceutical Technology, 2014, https://www.pharmtech.com/view/adapter-aids-positioning-syringes-autoinjectors

39. ASTM E2910-12, Standard Guide for Preferred Methods for Acceptance of Product, 2018, ASTM International, https://www.astm.org/e2910-12r18.html

40. EMA Sampling and Testing, 2019, https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/compliance-marketing-authorisation/sampling-testing

41. ANSI/ASQ Z1.4, Quality Standards, 2003, https://asq.org/quality-resources/z14-z19?srsltid=AfmBOookYlqMIDtOTau_oZbzycHPOl7a1VyxcIUfGLZ8qw01ryll5iw1

42. ISO 2859-1, Sampling Procedures for Inspection by Attributes, 2026, https://www.iso.org/standard/85464.html

43. Engineering Statistics Handbook: Process Capability Indices, Chapter 6, NIST, 2012, https://www.itl.nist.gov/div898/handbook/

44. ISO 20457 Plastics Moulded Parts - Tolerances and Acceptance Conditions, 2018, https://www.iso.org/standard/68097.html